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Abstract
Purpose Faecal incontinence (FI) is distressing, significantly
reduces quality of life (QoL) and has few pharmacological
treatments. The α1-adrenoceptor agonist NRL001 (1R,2S-
methoxamine hydrochloride) improves anal sphincter tone.
NRL001 efficacy was evaluated by changes in Wexner scores
at week 4 vs. baseline in NRL001-treated patients compared
with placebo. Impact of NRL001 on QoL and safety were also
assessed.
Methods Four hundred sixty-six patients received NRL001
(5, 7.5 or 10 mg) or placebo as suppository, once daily over
8 weeks. Wexner score, Vaizey score and QoL were analysed
at baseline, week 4 and week 8. FI episodes and adverse
events were recorded in diaries.
Results At week 4, mean reductions in Wexner scores were
−3.0, −2.6, −2.6 and −2.4 for NRL001 5, 7.5, 10 mg and
placebo, respectively. All reduced further by week 8. As pla-
cebo responses also improved, there was no significant treat-
ment effect at week 4 (p=0.6867) or week 8 (p=0.5005). FI
episode frequency improved for all patients, but not signifi-
cantly compared with placebo (week 4: p=0.2619, week 8:
p=0.5278). All patients’ QoL improved, but not significantly
for all parameters (p>0.05) except depression/self-perception
at week 4 (p=0.0102) and week 8 (p=0.0069), compared
with placebo. Most adverse events were mild and judged
probably or possibly related to NRL001.
Conclusions All groups demonstrated improvement in ef-
ficacy and QoL compared with baseline. NRL001 was
well-tolerated without serious safety concerns. Despite
the improvement in all groups, there was no statistically
significant treatment effect, underlining the importance of
relating results to a placebo arm.
Keywords Faecal incontinence . Quality of life . Episode
frequency . Alpha-1 receptor agonist . NRL001
Introduction
Faecal incontinence (FI) is a distressing condition defined
as the inability to voluntarily control the passage of faecal
matter or gas through the anal canal and expel it at a
socially acceptable time and location [1]. It significantly
reduces psychological and emotional well-being and neg-
atively affects quality of life (QoL) [2, 3]. The feelings of
embarrassment and depression may be one of the expla-
nations why the majority of patients do not report FI to
their physician [4] and may be one of the main reasons
why only approximately one third of symptomatic
What does this paper add to the literature? All patients’ FI symptoms
improved, but the NRL001 effect was not significant when compared
with placebo. Unexpected and sustained symptom improvements in the
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patients seek medical help [5]. Estimates of the preva-
lence of FI vary depending on the population studied.
One survey of adults living in the US community showed
that approximately 8.3 % reported FI [6]. The incidence
of FI has been shown to be significantly higher in women
[7, 8], in patients with existing gastroenterological condi-
tions [8] and also significantly increases with age [9, 10].
The most recent and largest North American study found
that almost 20 % of healthy women had experienced FI
during the preceding 12 months [9].
Mild FI may be improved with conservative therapies
including lifestyle changes and biofeedback retraining.
Pharmacological interventions remain poorly investigated,
and a recent review of clinical trials suggests that many
therapies do not significantly improve symptoms [11].
Surgery is increasingly performed in FI due to the failure
of conservative and pharmacological therapies. However,
many subjects are poor surgical candidates and long-term
success rates are variable [12–14]. The lack of a univer-
sally effective, surgical method has led to the develop-
ment of numerous complex options including an artificial
bowel sphincter, magnetic anal sphincter, stimulated
graciloplasty and sacral nerve stimulation [15–18]. These
procedures might lead to definite improvement, but the
morbidity profiles emphasize the need for effective
pharmacological treatments.
The internal anal sphincter (IAS) muscle exists in a natural
state of tonic contraction. Naturally occurring degeneration
due to ageing can result in a loss of smooth muscle tone,
and in addition, reduced contractile function might lead to
uncontrollable bowel movements [19]. The IAS muscles
receive excitatory innervations to mediate contraction or
relaxation via the α- or β-adrenergic receptors, respectively.
Therefore, the adrenergic sympathetic nervous system could
be targeted therapeutically with a view to restoring smooth
muscle tone and improving FI symptoms [20].
Topical application of the selective α1-adrenoceptor
agonist phenylephrine increased anal sphincter tone as
measured by mean anal resting pressure (MARP) in both
healthy subjects and patients with FI [21, 22]. Symptomatic
improvement, however, was disappointing in a separate
phenylephrine study [23]. 1R,2S-Methoxamine hydro-
chloride (NRL001) is a highly selective α1-adrenoceptor
agonist that is approximately four times more potent
than phenylephrine at constricting porcine IAS tissue
in vitro [24]. Local administration of NRL001 to healthy
subjects and patients with FI has been shown to increase
MARP [25–27].
Therefore, the Libertas study—a multi-centre, double-blind,
randomized, placebo-controlled, dose-ranging clinical
study—was designed to primarily investigate the impact
of NRL001 on FI symptoms [28]. Secondary aims were to
assess patient QoL, safety profile and tolerability.
Methods
Ethics
Independent Ethics Committees approved this study, which
was conducted in accordance with Good Clinical Practice
and the Declaration of Helsinki, 2008. All patients provided
written informed consent prior to enrolment. This study was
registered at ClinicalTrials.gov (NCT01656720).
Study population
Patients aged 18 years or more with a diagnosis of FI (Wexner
score of 8–20 [29]) and an intact IAS on ultrasonography were
eligible for inclusion. Patients had to have FI for at least
6 months and two or more diary confirmed FI episodes per
week in the 4 weeks prior to screening. Patients were excluded
if there was evidence of external anal sphincter trauma, which
allowed for a more homogenous patient population by
reducing variation in anal tone and defects. Patients with
uncontrolled gastrointestinal, cardiovascular or obstructive
pulmonary diseases were excluded. Those suffering from
chronic liver disease, renal impairment or closed-angle glau-
coma or other conditions of light sensitivity and/or mydriasis
were also excluded. The patient demographics are described
in Table 1.
Study design
In brief, this was a multi-centre, phase II, double-blind, ran-
domized, placebo-controlled, parallel group, dose-ranging
study (Fig. 1). Patients were randomized in a 1:1:1:1 ratio as
follows: NRL001 5 mg, 7.5 mg, 10 mg or placebo in a 2-g
suppository to be self-administered once daily [28]. These
doses were based on results of a previous study of NRL001
in healthy volunteers [30].
This study was conducted from 27th of February 2012 to
30th of December 2013, in 55 European centres in the
Czech Republic, France, Germany, Hungary, Italy, Poland,
Spain, Sweden and the UK.
Patients were assigned a unique number based on the study
site number and the serial number of the patient at screening.
During randomization, eligible patients were assigned a
unique randomization number from the Interactive Web
Response System (IWRS; Premier Research Group Ltd,
UK) that was linked to two patient investigational medicinal
product packs. The investigator maintained a list of patient
names, assigned unique patient numbers and associated
assigned unique randomization numbers. The password-
protected randomization list was supplied by a statistician of
Premier Research Group Ltd using the Statistical Analysis
System (SAS) for Windows (SAS Institute Inc., USA) to
Pharmaceutical Development, Norgine Ltd, UK. NRL001
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and placebo were packed and labelled according to pertinent
regulations by the Sponsor. The randomization schedule
was then made available to the Premier Research Group
Ltd IWRS.
This was a double-blind study with all NRL001 and
placebo suppositories provided in the same packaging and
labelling. No person involved in conducting the study had
access to the randomization code before the blinding was
officially broken. However, in the case of an emergency that
required the investigator to be unblinded, the investigator was
allowed to obtain the randomization code via the IWRS.
The study period consisted of a 2-week run-in phase, an 8-
week treatment period and a 1-week post-treatment follow-up.
In total, the study comprised five visits to the study site.
Patients were screened on day 14. On day 1 (randomization),
patients received their first dose, provided the eligibility
criteria were met. Patients attended visits at week 2, week 4
and week 8. A follow-up telephone call was made at week 9 to
assess overall patient satisfaction and the duration of any
adverse event.
Patients received 70 suppositories in total—35 at week 1
and 35 at week 4—and were provided with an electronic diary
(e-Diary) to record details of suppository administration and
frequency and type of incontinence episodes.
The primary endpoint of this study was to determine the
efficacy of NRL001 as assessed by a change in the Wexner
Run-in – no  
treatment
Placebo / 2g suppository
5 mg NRL001 / 2g suppository
7.5 mg NRL001 / 2g suppository
10 mg NRL001 / 2g suppository
Follow Up
Day -14                    Day 1             Day 15          Day 29                 Day 57           Day 64
Visit 2
2 weeks 8 weeks 1 week
Visit 3 Visit 4 Visit 5 Follow-up Telephone callVisit 1
Screening Randomization 2-week 
Intermediate
4-week
Middle
8-week 
Final
Fig. 1 The Libertas study design
Table 1 Summary of patient demographic characteristics (safety population)
Variable NRL001 5 mg
(N= 114)
NRL001 7.5 mg
(N= 115)
NRL001 10 mg
(N = 122)
Placebo
(N = 112)
Total
(N= 463)
Age, years 61.4 (12.37) 62.4 (12.93) 62.9 (12.59) 61.4 (11.39) 62.1 (12.32)
Sex, n (%) Female 98 (86.0) 99 (86.1) 102 (83.6) 91 (81.3) 390 (84.2)
Male 16 (14.0) 16 (13.9) 20 (16.4) 21(18.8) 73 (15.8)
BMI (kg/m2) 26.4 (4.38) 26.6 (4.41) 26.8 (4.99) 27.2 (4.74) 26.8 (4.64)
Height (cm) 164.1 (8.36) 163.2 (7.53) 164.2 (8.37) 165.2 (8.61) 164.1 (8.23)
Weight (kg) 71.2 (13.80) 70.07 (11.82) 72.3 (14.26) 74.2 (14.75) 72.1 (13.73)
Ethnicity, n % White 110 (96.5) 113 (98.3) 116 (95.1) 106 (94.6) 445 (96.1)
Black or
African-
American
1 (0.9) 0 (0.0) 0 (0.0) 1 (0.9) 2 (0.4)
Asian 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.9) 2 (0.4)
Other 3 (2.6 %) 2 (1.7) 5 (4.1) 4 (1.3 14 (3.0)
Unless noted otherwise, values are expressed as mean (standard deviation)
n number of patients, BMI body mass index
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score at week 4 in patients receiving NRL001 compared with
those receiving placebo. Key secondary endpoints included
Vaizey scores and the number of FI episodes per week as
additional efficacy parameters at week 4 and week 8, as well
as patient QoL and satisfaction.
Sample collection and analysis
The Wexner scoring system consisted of the score sum of five
parameters (frequency of gas, liquid or solid incontinence,
need to wear a pad and lifestyle alterations) scored on a scale
of 0 (absent) to 4 (daily) [29]. A total score of 0 suggested full
continence and score of 20 complete FI. The Vaizey scoring
system was subsequently created by modifying to include two
additional questions assessing the ability to defer defecation
and use of antidiarrheal medication [31]; 0 suggested full
continence and 24 complete FI.
QoLwasmeasured using the FI quality of life (FIQoL) scale
[2] and the EQ-5D-5L Healthcare Questionnaire [32, 33] at
baseline, week 4 and week 8. The FIQoL scale ranged from
1 to 5, where 1 indicated lowest QoL and 5 the highest, andwas
produced by scoring statements based on lifestyle, coping/be-
haviour, depression/self-perception and embarrassment. The
EQ-5D-5L Healthcare Questionnaire assessed five parameters:
mobility, self-care, ability to perform usual activities,
pain/discomfort and anxiety/depression. It also included a vi-
sual analogue scale (VAS) for patients to record their self-rated
health state. The frequency of FI episodes was assessed using
recordings made in the e-Diaries.
Pharmacokinetic relationships between NRL001 concen-
tration and either efficacy or adverse effects were assessed at
week 1 (pre-dose and 1, 2 and 4 h post-dose) and week 4.
Safety assessment
Adverse events were recorded from screening until the end of
the study and were coded using MedDRA Version 14.0 or
higher. All adverse events were graded as mild, moderate or
severe according to intensity, and the relationship to NRL001
was classified as probable, possible or unrelated. The final
phone call was used to assess the patients’ global perception
of efficacy and the duration of adverse events.
Blood pressure, pulse rate, physical examination, urine
analysis and 12-lead electrocardiogram measurements were
recorded at each visit. Twenty-four-hour Holter monitoring
was performed at screening and week 2. Patients also had
blood samples taken at screening, week 2 and week 8 for
laboratory safety tests of clinical chemistry and haematology.
Statistical analysis
The sample size was calculated using a responder rate. Active
treatment was classed as a success if it showed a 20 %
improvement over placebo in the primary endpoint. With
80 % power and a two-sided level of significance of 0.05
(5 %), a minimum of 98 patients were required in each
treatment group to show a difference between rates of 25
and 45 %.
The primary endpoint was defined as the change relative to
baseline in Wexner score at week 4. Variation amongst the
four treatment groups was tested using an analysis of covari-
ance (ANCOVA) with screening as covariate, and statistical
significance was defined as p<0.05. Differences between
placebo and each of the three active treatment groups are
presented with a 95 % confidence interval (CI). Where signif-
icant variation was seen, pairwise differences between placebo
and each of the three active treatment groups were tested by
calculating CIs for the difference in least square means be-
tween placebo and active treatment using Dunnett’s method
within the ANCOVA. Differences in the number of FI epi-
sodes and the Vaizey, and FIQoL scores were tested using
the same statistical methods as the primary endpoint.
Changes in the EQ-5D-5L questionnaire from screening to
week 4 and week 8, and the overall assessment of patient
satisfaction at week 9 were tested using the Wilcoxon test.
Plasma concentrations of NRL001 were summarized for
each treatment group, and the relationship between estimated
areas under the concentration-time curve (AUC) determined.
Study populations included the safety population, all
patients who received any dose of NRL001 or placebo; the
modified intent to treat (mITT) population, which was used to
analyse efficacy and QoL, and included all patients who
received any dose of NRL001 or placebo and had data on
the Wexner score at both screening and week 4; and the phar-
macokinetic population, all patients who received any dose of
NRL001 and had valid pharmacokinetic data.
Results
Patients
Approximately 580 patients were planned to be screened to
obtain 400 evaluable patients. A total of 466 patients were
randomized and 463 (safety population) received at least one
dose of NRL001 (5 mg, n=114; 7.5 mg, n=115; 10 mg,
n= 122) or placebo (n= 112, Fig. 2). The mean age was
62.1 years and the majority were female (390/463 [84 %],
Table 1). The mITT population comprised 440 patients
(NRL001 5 mg, n=108; 7.5 mg, n=108; 10 mg, n= 117
and placebo n=107). A total of 23 patients from the safety
population were excluded from the mITT population (15 be-
cause of missing data on the Wexner score at baseline and/or
week 4, and a further eight patients were excluded as a
consequence of GCP deviations at one particular study
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centre). The pharmacokinetic population comprised 325
patients (NRL001 5 mg, n = 105; 7.5 mg, n = 106; and
10 mg, n=114).
Efficacy
At baseline, mean Wexner scores were similar between the
NRL001 and placebo groups (12.9±3.1 for NRL001 5 mg,
13.3±3.2 for NRL001 7.5 mg, 13.3±3.1 for NRL001 10 mg
and 12.9±3.0 for placebo, Table 2). No statistically significant
treatment effect was detected at week 4 or week 8 (Fig. 3).
Vaizey scores and the number of FI episodes per week
decreased from screening to week 4 for all treatment groups
and had decreased further byweek 8. However, no statistically
significant treatment effect was detected (Table 2). Responses
in the placebo-treated group were similar to those receiving
NRL001 and persisted through the 8-week study period.
Quality of life
At baseline, mean FIQoL scores were similar for NRL001 and
placebo groups in all four parameters (Fig. 4). Scores for each
parameter increased in all treatment arms at week 4 and in-
creased further by week 8. Statistically significant improve-
ments of NRL001 treatment effects compared with placebo
were observed on depression/self-perception at week 4
(p=0.0102) and week 8 (p=0.0069) but not for the other
scales (p> 0.05). Analysis of 95 % CIs revealed a statis-
tically significant treatment difference between NRL001
5 mg and placebo for depression/self-perception at both
week 4 (treatment difference 0.25 [95 % CI 0.06–0.44])
and week 8 (treatment difference 0.28 [95 % CI 0.08–0.47])
but not for other doses.
There was a significant increase in overall assessment of
health according to the VAS at week 4 in all NRL001 treat-
ment groups compared with placebo (p=0.0478), but VAS
was not significantly improved at week 8 in any of the treat-
ment groups compared with placebo (p > 0.05, data not
shown). Analysis of EQ-5D-5L data showed marginal differ-
ences compared with placebo at week 4 and week 8 for some
of the parameters (Table 3).
Pharmacokinetics
There was a dose-dependent increase in the plasma concen-
tration of NRL001 with mean AUC values of 15.4±8.7 ng/
mL/h for NRL001 5 mg, 23.9±12.9 ng/mL/h for NRL001
7.5 mg and 32.2±17.0 ng/mL for NRL001 10 mg (pharma-
cokinetic population). No NRL001 was detected in the
placebo-treated group (data not shown).
Patient satisfaction
Seventy-one (82.6 %), 59 (74.7 %) and 72 (75.8 %) patients
who received NRL001 5, 7.5 and 10 mg, respectively, and 77
(85.6 %) patients who received placebo said they would
choose to take the same medication again. There were no
statistically significant differences between NRL001 groups
and placebo (p > 0.05) for overall assessment of patient
satisfaction (performance of study medication; taking study
medication again and the change in QoL).
Randomized
N=466
Patient withdrawal: 2
Adverse event: 1
Protocol violation: 1
Non-compliance with 
study drug: 1
NRL001 5 mg
N=115
Screened
N=585
NRL001 7.5 mg
N=115
NRL001 10 mg
N=123
Placebo
N=113
99 Completed
Populations analyzed
Safety: 115
mITT: 108
PK: 106
Patient withdrawal: 4
Adverse event: 3
Protocol violation: 1
Other: 1
Patient withdrawal: 5
Adverse event: 7
Protocol violation: 4
Other: 1
Physician’s decision: 1
Study termination by 
sponsor: 1
Patient withdrawal: 2
Adverse event: 8
Protocol violation: 4
Other: 1
Physician’s decision: 1
106 Completed
Populations analyzed
Safety: 114
mITT: 108
PK: 105
Screening failure: 97
Patient withdrawal: 14
Adverse event: 1
Protocol violation: 1
Other: 2
Physician’s decision: 1
Technical problem: 3
104 Completed
Populations analyzed
Safety: 122
mITT: 117
PK: 114
108 Completed
Populations analyzed
Safety: 112
mITT: 108
PK: 0
Fig. 2 Consort patient flow
diagram
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Fig. 4 Patients’ mean FIQoL scores at screening, week 4 and week
8 (mITT population) for the four parameters: lifestyle (a), coping/
behaviour (b), depression/self-perception (c) and embarrassment
(d). p values for treatment effects calculated using ANCOVA with
screening as covariate. *Pairwise differences between placebo and
NRL001 5 mg were statistically significant at both week 4 and week
8 at the 95 % CI, calculated using Dunnett’s method within
ANCOVA
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Safety
Overall, 212/463 (46 %) patients reported 494 adverse events
(Table 4). In general, more patients in the NRL001-treated
groups were affected by adverse events (45.2–52.5 %) than
those who received placebo (36.6 %). The most frequent ad-
verse events following dosing with NRL001 (paraesthesia,
feeling cold and piloerection) were expected, generally mild
in intensity and judged to be attributed to the pharmacological
effect of NRL001, but the relationship between adverse events
and efficacy of NRL001 was not explored.
Eighteen patients (3.9 %) experienced adverse events lead-
ing to withdrawal from the study, and 20 patients (4.3 %) ex-
perienced adverse events that led to discontinuation of the study
drug. The number of patients whose adverse events led to dis-
continuation of the study drug was higher in the NRL001-
treated groups than placebo (19/20 receiving NRL001; 1/20
receiving placebo). One patient who received NRL001 10 mg
developed severe cardiac failure following hospitalization from
urosepsis that was considered serious and judged possibly re-
lated to study drug, although this resolved by the end of the
study. There were no reports of bradycardia during the study.
Discussion
Wexner scores decreased across all NRL001 treatment arms
compared with baseline. However, a marked placebo response
Table 3 Wilcoxon p values
calculated for the change in
the EQ-5D-5L Healthcare
Questionnaire from screening
at week 4 and week 8 (mITT
population)
Question Comparison of
NRL001 vs. placebo
Wilcoxon p value
Week 4 Week 8
Mobility 5 mg 0.00353 0.34432
7.5 mg 0.16309 0.68848
10 mg 0.05261 0.78593
Self-care 5 mg 0.12285 0.32080
7.5 mg 0.07852 0.49652
10 mg 0.44415 0.61766
Activity 5 mg 0.0007561 0.03675
7.5 mg 0.06087 0.02401
10 mg 0.02297 0.13918
Pain 5 mg 0.15276 0.28540
7.5 mg 0.33317 0.57655
10 mg 0.14695 0.38680
Anxiety/depression 5 mg 0.18180 0.07648
7.5 mg 0.73124 0.68457
10 mg 0.34466 0.94216
mITT modified intent to treat
Table 4 Adverse events reported by ≥3 % of patients (safety population)
NRL001 5 mg
(N= 114)
NRL001 7.5 mg
(N= 115)
NRL001 10 mg
(N = 122)
Placebo
(N= 112)
Total (N= 463)
n (%) e n (%) e n (%) e n (%) e n (%) e
Any event 55 (48.2) 107 52 (45.2) 140 64 (52.5) 162 41 (36.6) 85 212 (45.8) 494
Paraesthesia 9 (7.9) 9 14 (12.2) 18 17(13.9) 21 1 (0.9) 1 41 (8.9) 49
Headache 1 (0.9) 1 6 (5.2) 7 5 (4.1) 5 6 (5.4) 6 18 (3.9) 19
Feeling cold 11 (9.6) 11 7 (6.1) 7 12 (9.8) 13 3 (2.7) 4 33 (7.1) 35
Chills 8 (7.0) 8 6 (5.2) 8 8 (6.6) 10 0 (0.0) 0 22 (4.8) 26
Piloerection 5 (4.4) 7 8 (7.0) 9 14 (11.5) 15 0 (0.0) 0 27 (5.8) 31
Urinary tract infection 4 (3.5) 7 1 (0.9) 1 5 (4.1) 5 4 (3.6) 4 14 (3.0) 17
Other 17 (14.9) 64 10 (8.7) 90 3 (2.5) 93 27 (24.1) 70 57 (12.3) 317
Includes events occurring in less than 3 % of patients
n number of patients, e number of events
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was observed during the entire 8-week treatment period such
that no statistically significant treatment effect was observed
when comparing active treatment with placebo. Secondary
endpoints showed similar findings, with marked improve-
ments in response to NRL001 accompanied by a notable
placebo response of similar magnitude. However, NRL001
had a statistically significant effect on some QoL assessments
at week 4 and week 8 compared with placebo: NRL001 sig-
nificantly improved patients’ self-assessed mobility, activity
and overall health at week 4 and activity at week 8. Although
these were not paired with statistically significant improve-
ments in Wexner scores, correlations were apparent.
Decreases in Wexner and Vaizey scores, and frequency of FI
episodes complemented QoL improvements; associations have
proven to be significant in previous validation studies [34–36].
The reduction in Wexner score after 8 weeks of treatment
when compared with baseline was highly significant for all
NRL001 treatment arms (p< 0.0001) as well as placebo.
Pharmacokinetic data demonstrated a dose-dependent
increase in plasma concentrations of NRL001. Visual inspec-
tions of the data indicated that there was no dose-proportional
improvement in any of the endpoints, although this was not
tested statistically. A dose-dependent increase in MARP was
reported in a study in which NRL001 was administered to
healthy volunteers [27]. Assessment of anorectal physiology
may have provided useful information regarding the mecha-
nistic insight of the drug. However, anorectal physiology as-
sessments were likely to have significantly adversely affected
enrolment feasibility and cost. Furthermore, evaluations of
anorectal physiology, such as anorectal manometry assess-
ments, are often also poorly correlated with patient outcomes
[37, 38]. This has been hypothesized to be due to a stenosing
effect following surgery, increasing the resistance to blood
flow through the anus, masking physiological alterations de-
tected in pressure measurements [39]. Additionally, MARP
was not assessed in this current study due to the difficulties
standardizing methodologies in a large patient population and
the suggestion that many therapies do not significantly
improve symptoms of FI, despite their positive effect on
MARP [11]. This and the lack of dose-response in symp-
tom improvement in the current study argue strongly that
biological endpoints such as MARP are poor markers of
patient outcomes. The FI episodes reported in this study
encompassed all forms of incontinence. It was considered
that analysis of faecal matter incontinence episodes
(FMIE), which excludes flatus, might reveal a more ro-
bust treatment effect. Consequently, although not present-
ed here, FMIE for each active treatment group at both
week 4 and week 8 were analysed and compared with
those of placebo-treated patients but no significant treat-
ment effect was observed. As such, evaluation of Wexner
scores as the primary endpoint for this study was consid-
ered appropriate.
The reported adverse events were similar to those in previ-
ous studies (paraesthesia, chills and piloerection) and were
thought to be a direct result of increased α1-adrenoceptor
stimulation [25–27, 30, 40, 41]. Visual inspections of the data
indicated that adverse events were less frequent in the
placebo-treated group than any of the NRL001-treated groups.
There also appeared to be no dose-relationship in the frequen-
cy of adverse events reported across the three active treatment
groups, although not tested statistically. Safety assessments
did not show any new or previously unknown risks of
NRL001. Bradycardia—an expected effect ofα1-adrenoceptor
stimulation [42]—was not reported in any treatment group. A
meta-analysis of previous studies involving topical application
of NRL001 has shown that whilst patients generally experi-
enced a dose-dependent decrease in heart rate, bradycardia was
not clinically significant [43]. Therefore, the safety of NRL001
was deemed better than expected.
The inclusion criteria for this study included a screening
Wexner score of 8–20. Therefore, patient FI severities ranged
from relatively mild to very severe [29]. It is possible that the
severity ofWexner score at screening was an important factor;
however, a descriptive post hoc analysis (Norgine data on file)
was unable to show any difference in effect between patients
with baseline Wexner score of 8–11, 12–15 or 16–20. This
inclusion criterion was designed to make the results of this
study comparable with those of other recent studies that assess
new therapeutic options for treatment of FI (not direct surgical
repair) and use the Wexner score to define their patient
population [44–46]. Prior exposure of patients to biofeedback
therapy, a conservative approach employed to treat FI based
on the theories of operant conditioning, was not taken into
consideration. Patients receiving conservative treatments
display sustained FI symptom improvement for up to a year,
but some studies hypothesize that beneficial effects relate
more to the relationship with the therapist than the technical
aspects of the therapy and many responders lose the effect
over time [47]. It is possible that any patients naive to biofeed-
back therapy included in this study may have benefited more
from inclusion in the study rather than the pharmacological
substance itself. Also, any patient in whom biofeedback
therapy had previously improved symptoms, but which was
lost over time, might be more likely to have improvement in
their symptoms again. As such, this study may have benefited
by including a run-in period with biofeedback therapy to
exclude those patients who would have attained adequate FI
symptom relief from conservative treatments. However, this is
likely to have restricted the number of patients eligible for
inclusion.
A number of important factors made the Libertas study
unique: There have been few similarly designed studies in
FI involving this number of patients; this study was the first
testing NRL001 in a broad population of patients; and it
employed innovative strategies, including the use of an
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outreach program, to recruit patients whilst taking into
account the sensitivity of the condition [28], and finally the
comparison of subjects’ responses to NRL001 with placebo,
rather than solely with screening measurements. Given the
positive effects of NRL001 in previous studies [25–27], the
findings of the current study are highly relevant, confirming
the importance of a placebo group.
Predictors of the placebo response have been a focus of
many studies with potentially significant impact on clinical
trials. The placebo response observed in this study was larger
than expected and did not decline during the 8-week treatment
period. The placebo suppositories used in this study com-
prised 0.03-g colloidal anhydrous silica and 1.97-g hard fat.
NRL001 suppositories contained reduced amounts of fat to
compensate for the addition of NRL001. The route of admin-
istration of a treatment is known to impact the extent to which
a placebo response may be elicited. A review of placebo
responses observed in clinical trials of migraine treatments
concluded that interventions administered at the site of pain
elicit a greater placebo response than those administered at a
distance [48]. As such, the placebo response observed in this
study is likely to have been more robust than a placebo re-
sponse observed had the intervention for FI been administered
orally. Furthermore, progressively invasive treatments are
coupled with a more robust placebo response: One study of
a migraine treatment reported pain relief of 39 % following
administration of placebo as a suppository, whereas others
have demonstrated pain relief of 39–32 % following adminis-
tration via nasal sprays [48]. Placebo-controlled studies in
patients with FI have also shown unexpected high response
rates after saline injection [49] or sham electrical stimulations
[50, 51]. As well as the route of administration, the small
sample sizes of these studies may have contributed to the lack
of clinical effect in these studies. This was one factor that the
Libertas study aimed to mitigate, and by using a broad and
ample study population, it was hoped that the sample size
would be sufficient to demonstrate a significant clinical effect.
These findings suggest that FI studies that report a positive
treatment effect but do not make comparisons with placebo
should perhaps be interpreted with caution.
Treatment-specific restrictions on conservative thera-
pies such as dietary advice, behavioural changes or
muscle-strengthening exercises were not imposed on pa-
tients during this study. Therefore, active treatment groups
and the placebo-treated group should have received simi-
lar treatments throughout. Although conservative medical
treatments were not analysed here, a Cochrane review of
21 individual studies found little evidence to support the
therapeutic benefits of anal sphincter exercises or biofeedback
therapy alone [52], and so the use of these by placebo-treated
patients would have been unlikely to account for their robust
response. Patients were also required to report any concomi-
tant medications taken throughout the study in their e-Dairies.
A total of 17 patients used drugs for the treatment of functional
gastrointestinal disorders during the course of the study, al-
though there was imbalance in relation to treatment group.
Therefore, the use of concomitant medications or conservative
medical treatments was not thought to differ between treat-
ment groups and thus contribute to the response observed in
the placebo-treated group.
A recent review suggested that the placebo response is also
related to cognitive constructs, such as locus of control—the
extent to which individuals believe they can control events
[53, 54]. In particular, a placebo response is seen in those with
an external locus of control, meaning participants have a
strong belief that outcomes are determined by factors external
to their control [55, 56]. Additional factors that appear to
minimize the placebo response in gastroenterology studies
are the use of a randomized, double-blind, controlled,
parallel group study design, with dosing taking place no
more than once daily [57, 58], all of which were imple-
mented in this study.
In conclusion, patients in this study displayed an im-
provement in FI symptoms in all parameters tested
throughout the duration of this 8-week study. This was
also reflected in improvements of QoL and positive pa-
tient satisfaction. However, no statistically significant
treatment effects of NRL001 were seen compared with
placebo because of the comparable response observed in
this group. This finding confirms the importance of robust
study design in clinical trials to include appropriate con-
trol and comparator groups and should be considered
when interpreting other studies in this therapeutic area.
Libertas was intended to provide a framework for future
studies allowing clear endpoints to be derived. It is hoped
that, despite the lack of a treatment effect in the Libertas
study, lessons learned from its design and conduct will
ultimately benefit patients suffering with FI.
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